'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug: https://t.co/wNFL6nwmEw

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright &amp; Co. report.

$AXSM #Alzheimers #healthcare #stocks https://t.co/AlhnVAjs5w